PPAs – Ready to make a long-term commitment to zero carbon?
December 14, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Energy, sustainability
As an industry that consumes a large amount of energy, the pressure is on for the pharmaceutical sector to achieve …
PPAs – Ready to make a long-term commitment to zero carbon?
December 14, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Energy, sustainability
As an industry that consumes a large amount of energy, the pressure is on for the pharmaceutical sector to achieve …
FDA issues emergency use authorisation for Pfizer-BioNTech vaccine
December 14, 2020Sales and Marketing COVID-19, FDA, US, Vaccine
The US Food and Drug Administration has approved the Pfizer-BioNTech COVID-19 vaccine for emergency use in those aged 16 and …
AstraZeneca to buy Alexion in $39 billion deal
December 14, 2020Sales and Marketing Alexion, AstraZeneca, merger
British-Swedish AstraZeneca is set to acquire American biopharmaceutical company Alexion for $39 billion, in a move that will see a …
Pfizer and Merck KGaA secure CHMP recommendation for Bavencio in Europe for first-line maintenance of urothelial carcinoma
December 14, 2020Sales and Marketing Bavencio, CHMP, EMA, Merck, Pfizer, pharma, urothelial carcinoma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given its recommendation for …
European approval for AstraZeneca’s Trixeo Aerospace in moderate to severe COPD
December 14, 2020Sales and Marketing AstraZeneca, COPD, EMA, Europe, Trixeo Aerosphere
The European Medicines Agency (EMA) has announced the approval of AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) in the European Union …
Novartis and Incyte’s ruxolitinib fails to show benefit in COVID-19 at Phase 3
December 14, 2020Research and Development, Sales and Marketing COVID-19, Incyte, Novartis
Novartis has unveiled that its JAK 1/2 tyrosine kinase inhibitor ruxolitinib fell short of its main efficacy goal in the …
Top Ten most popular articles on Pharmafile.com this week
December 11, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, COVID-19, Pfizer, Vaccine, pharma, top 10
With just around three weeks until the end of a long year, rapidly emerging news around the leading COVID-19 vaccine …
Janssen’s esketamine nasal spray secures CHMP recommendation in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder
December 11, 2020Medical Communications EMA, Europe, Spravato, depression
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has moved to recommend Janssen’s …
Sanofi/GSK COVID-19 vaccine development delayed after failing to induce strong response in over-50s
December 11, 2020Medical Communications, Research and Development COVID-19, GSK, Sanofi, Vaccine
Sanofi and GlaxoSmithKline have taken the decision to delay the development programme for their adjuvanted recombinant protein-based COVID-19 vaccine after …
FDA advisory panel recommends US approval of Pfizer/BioNTech’s COVID-19 vaccine
December 11, 2020Medical Communications, Sales and Marketing COVID-19, FDA, Vaccine
An advisory panel on behalf of the FDA has strongly recommended that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 be approved …
NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine
December 11, 2020Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine
NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …
Hackers breach EMA server to steal data on Pfizer/BioNTech’s COVID-19 vaccine
December 10, 2020Research and Development COVID-19, EMA, Vaccine
Pfizer and BioNTech’s jointly-developed COVID-19 vaccine, which this week began to rolled out to elderly patients in the UK after …
NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer
December 10, 2020Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda
NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …
UAE reveals 86% effiacy for Sinopharm’s COVID-19 vaccine
December 10, 2020Research and Development COVID-19, Sinopharm, UAE, Vaccine
The Health Ministry of the United Arab Emirates has unveiled the first known efficacy data for the COVID-19 vaccine candidate …
Lilly’s tirzepatide generates significant reductions in weight and blood sugar in type 2 diabetes patients
December 10, 2020Research and Development Eli Lilly, diabetes, tirzepatide
Eli Lilly has announced new data for its glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, showing …
AbbVie unveils new Phase 3 upadacitinib data in moderate to severe ulcerative colitis
December 10, 2020Research and Development AbbVie, upadacitinib
AbbVie has announced data from the first of two Phase 3 studies investigating the efficacy of upadacitinib in treating moderate …
Pharmafile.com’s weekly COVID-19 news round-up
December 9, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Top 5, pharma
COVID-19 vaccine news continues to roll in and continues to be positive, with AstraZeneca now releasing Phase 3 data that …
Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer
December 9, 2020Research and Development Kisqali, Novartis, breast cancer
Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …
MHRA warns patients with history of significant allergic reactions not to receive Pfizer/BioNTech COVID-19 vaccine
December 9, 2020Research and Development COVID-19, MHRA, UK, Vaccine
While the rolling out of Pfizer and BioNTech’s COVID-19 in the UK this week marked a historic moment in a …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
